NDAORAL-21TABLET
Approved
Jan 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORTHO-NOVUM 10/11-21 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1982.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 10/11-21 is a biphasic oral contraceptive tablet combining ethinyl estradiol and norethindrone, approved in 1982 for pregnancy prevention. It works by suppressing ovulation through estrogen and progestin receptor agonism. This is a legacy branded hormonal contraceptive in a crowded generic-dominated market.
LOE Approaching
Product is in terminal lifecycle stage with high competitive pressure (30/100), indicating a mature, declining franchise with lean team staffing and defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on ORTHO-NOVUM represents a mature product lifecycle role focused on market defense, generic price competition, and patient retention rather than innovation or growth. Career progression is constrained by the product's limited strategic importance within J&J's contraceptive portfolio and declining revenue trajectory.
Brand Manager
Worked on ORTHO-NOVUM 10/11-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.